Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bridging integrator 3 (BIN3) is a member of the BAR domain protein family, which bind to cell membranes, regulate actin dynamics, and contribute to processes such as cytokinesis and septation by helping localize F-actin. BIN3 contains a single BAR domain predicted to form coiled-coil structures allowing dimerization, interaction with small GTPases, and sensing or inducing membrane curvature[2][5]. The protein is implicated in endocytosis, membrane trafficking, and other forms of intracellular transport, and plays roles in the regulation of cell shape and division[2][5]. In cancer biology, lower expression of BIN3 correlates with poorer prognosis in several cancers, is associated with altered immune cell infiltration, and may function as a tumor suppressor, particularly in esophageal carcinoma[1]. Beyond oncology, genetic studies have implicated BIN3 in neurodevelopmental disorders, such as autism spectrum disorder[2]. There are currently no approved drugs or direct pharmacological modulators targeting BIN3.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bridging integrator 3 (BIN3).